Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2023-09-27 Interim / Quarterly Rep…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Interim Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 INTERIM REPORT' and contains detailed financial highlights, management discussion and analysis, and interim consolidated financial statements such as profit or loss, comprehensive income, financial position, changes in equity, and cash flows. The content covers a six-month period ended June 30, 2023, which is typical for an interim or quarterly report. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a full interim financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-09-27 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It details repurchases of shares on various dates, quantities, prices, and confirms compliance with listing rules of the Stock Exchange of Hong Kong. The content is focused on reporting share repurchase transactions and capital changes, not on financial results, management commentary, or other report types. The document is about share repurchase disclosures, which aligns with the category for company buying back its own shares. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length and detail support a confident classification.
2023-09-26 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES COMPLETION OF ENROLLMENT OF 120 PATIENTS IN THE PHASE III CLINICAL TRIAL OF FASN INHIBITOR ASC40 COMBINED WITH BEVACIZUMAB FOR TREATMENT OF RECURRENT GLIOB
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the completion of enrollment of 120 patients in a Phase III clinical trial. It provides details about the clinical trial design, patient numbers, and scientific background but does not contain financial data, regulatory filings, or report attachments. The document is relatively short (4334 characters) and is an announcement of a business development event rather than a financial or regulatory report. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a business update announcement related to clinical trial progress, which is best classified under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2023-09-26 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It details repurchases of shares on various dates, including quantities and prices, and confirms compliance with listing rules of the Stock Exchange of Hong Kong. The content is focused on reporting share repurchase transactions and changes in issued shares, not on financial results, management changes, or other report types. This matches the description of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares. The document length is substantial and contains detailed transactional data, confirming it is the report itself, not just an announcement. Therefore, the correct classification is POS (Transaction in Own Shares).
2023-09-25 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It details repurchases of shares on various dates, quantities, and prices, confirming compliance with listing rules. The content focuses on share repurchase activities and capital changes rather than financial results, management changes, or legal matters. The document is about share buybacks and changes in issued share capital, which fits the category of 'Transaction in Own Shares' (POS). The document length is 11,848 characters, indicating it is a full disclosure rather than a brief announcement or certification. Therefore, the appropriate classification is POS with high confidence.
2023-09-21 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed tables of repurchases of shares, dates, quantities, prices, and confirmations that these repurchases comply with listing rules of the Stock Exchange of Hong Kong. The document is a regulatory disclosure about share repurchases and changes in issued shares, not a financial report or earnings release. It is a formal notification of transactions in the company's own shares (share buybacks). Therefore, the document fits the category of 'Transaction in Own Shares' (POS). The document length and content confirm it is not a brief announcement but a detailed disclosure report on share repurchases.
2023-09-20 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.